News >

Emerging Agents Spur Optimism in Myeloma

Brandon Scalea
Published: Monday, May 06, 2019

Saurabh Chhabra, MD, MS

Saurabh Chhabra, MD, MS

The addition of elotuzumab (Empliciti) to the treatment arsenal for relapsed/refractory myeloma is arguably the biggest advance made in the space within the past year, according to Saurabh Chhabra, MD, MS. However, antibody-drug conjugates and CAR T-cell therapies are also making headway within the paradigm.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication